Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
361
Recruiting Now
361
Top Conditions in Phase 1 / Phase 2
NCT05719701 Phase 1, Phase 2
Recruiting
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Rela...
Condition
Relapsed and/or Refractory Multiple Myeloma
Enrollment
80 pts
Location
China
Sponsor
Beijing InnoCare Pharma Tech C
NCT06421519 Phase 1, Phase 2
Recruiting
Different Levels of BiPAP
Condition
Bronchopulmonary Dysplasia
Enrollment
21 pts
Location
United Kingdom
Sponsor
King's College Hospital NHS Tr
NCT06405230 Phase 1, Phase 2
Recruiting
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracel...
Condition
Lung Cancer, Non-Small Cell
Enrollment
40 pts
Location
United Kingdom
Sponsor
GlaxoSmithKline
NCT06809530 Phase 1, Phase 2
Recruiting
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Peme...
Condition
Leptomeningeal Metastasis
Enrollment
34 pts
Location
China
Sponsor
Guangzhou Medical University
NCT07193511 Phase 1, Phase 2
Recruiting
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Pati...
Condition
Solid Tumor Cancer
Enrollment
355 pts
Location
United States
Sponsor
Avenzo Therapeutics, Inc.
NCT06731868 Phase 1, Phase 2
Recruiting
Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tar...
Condition
Tardive Dyskinesia (TD)
Enrollment
120 pts
Location
China
Sponsor
Luye Pharma Group Ltd.
NCT06376136 Phase 1, Phase 2
Recruiting
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profi...
Condition
Advanced Solid Tumors
Enrollment
216 pts
Location
China
Sponsor
Bio-Thera Solutions
NCT06759064 Phase 1, Phase 2
Recruiting
Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Ca...
Condition
Cancer of Stomach, Adenocarcinoma
Enrollment
24 pts
Location
China
Sponsor
Qilu Hospital of Shandong Univ
NCT07265349 Phase 1, Phase 2
Recruiting
A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Trea...
Condition
Coronary Artery Bypass Grafting (CABG)
Enrollment
51 pts
Location
China
Sponsor
Tasly Pharmaceutical Group Co.
NCT04729543 Phase 1, Phase 2
Recruiting
MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer
Condition
Melanoma
Enrollment
20 pts
Location
Netherlands
Sponsor
Erasmus Medical Center
NCT06188702 Phase 1, Phase 2
Recruiting
S095035 as a Single Agent and in Combination in Adult Participants With Advanced...
Condition
MTAP-deleted Solid Tumors
Enrollment
342 pts
Location
United States, Australia, Denmark
Sponsor
Servier Bio-Innovation LLC
NCT06885034 Phase 1, Phase 2
Recruiting
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other ...
Condition
Gastrointestinal Neoplasms
Enrollment
320 pts
Location
United States, Australia, Belgium
Sponsor
GlaxoSmithKline
NCT01371630 Phase 1, Phase 2
Recruiting
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acu...
Condition
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Enrollment
276 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT06682780 Phase 1, Phase 2
Recruiting
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Condition
Advanced Solid Tumor
Enrollment
320 pts
Location
China
Sponsor
LaNova Medicines Limited
NCT06049290 Phase 1, Phase 2
Recruiting
A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Mult...
Condition
Relapsed/Refractory Multiple Myeloma
Enrollment
342 pts
Location
China
Sponsor
Nanjing Leads Biolabs Co.,Ltd
NCT07083323 Phase 1, Phase 2
Recruiting
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
Condition
Advanced Solid Tumor
Enrollment
262 pts
Location
China
Sponsor
Sichuan Huiyu Pharmaceutical C
NCT06878560 Phase 1, Phase 2
Recruiting
Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients Wi...
Condition
ESRD (End-Stage Renal Disease)
Enrollment
50 pts
Location
United States
Sponsor
United Therapeutics
NCT05849480 Phase 1, Phase 2
Recruiting
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxalip...
Condition
Biliary Cancer
Enrollment
60 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT05875168 Phase 1, Phase 2
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Condition
Advanced Solid Tumor
Enrollment
540 pts
Location
United States, Belgium, Canada
Sponsor
Daiichi Sankyo
NCT07118891 Phase 1, Phase 2
Recruiting
Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause
Condition
Vasomotor Symptoms Associated With Menopause
Enrollment
136 pts
Location
Canada
Sponsor
AbCellera Biologics Inc.
NCT04711824 Phase 1, Phase 2
Recruiting
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Phys...
Condition
Breast Cancer
Enrollment
41 pts
Location
United States
Sponsor
Colette Shen
NCT07038824 Phase 1, Phase 2
Recruiting
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Ski...
Condition
Duchenne Muscular Dystrophy (DMD)
Enrollment
24 pts
Location
Belgium, Italy, Netherlands
Sponsor
Entrada Therapeutics, Inc.
NCT05894824 Phase 1, Phase 2
Recruiting
T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Ju...
Condition
Gastric Cancer
Enrollment
58 pts
Location
South Korea
Sponsor
Yonsei University
NCT06552559 Phase 1, Phase 2
Recruiting
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-...
Condition
B-cell Lymphoma Recurrent
Enrollment
37 pts
Location
South Korea
Sponsor
Samsung Medical Center
NCT06137014 Phase 1, Phase 2
Recruiting
Fortified Oral Rehydration Therapy for Pediatric Diarrhea
Condition
Acute Gastroenteritis
Enrollment
72 pts
Location
United States
Sponsor
Paul A Breslin